Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience – report of an expert meeting
dc.contributor.author | Albrecht, P | |
dc.contributor.author | Bjorna, IK | |
dc.contributor.author | Brassat, D | |
dc.contributor.author | Farrell, R | |
dc.contributor.author | Feys, P | |
dc.contributor.author | Hobart, JC | |
dc.contributor.author | Hupperts, R | |
dc.contributor.author | Linnebank, M | |
dc.contributor.author | Magdic, J | |
dc.contributor.author | Oreja-Guevara, C | |
dc.contributor.author | Pozzilli, C | |
dc.contributor.author | Salgado, AV | |
dc.contributor.author | Ziemssen, T | |
dc.date.accessioned | 2018-08-01T08:45:43Z | |
dc.date.issued | 2018-10-05 | |
dc.identifier.issn | 1756-2864 | |
dc.identifier.issn | 1756-2864 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/11967 | |
dc.description.abstract |
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and re-treatment, and stopping criteria. This article summarizes the experts' opinions on how PR-fampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability. | |
dc.format.extent | 175628641880324-175628641880324 | |
dc.format.medium | Electronic-eCollection | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | SAGE Publications (UK and US) | |
dc.subject | multiple sclerosis | |
dc.subject | prolonged-release fampridine | |
dc.subject | real-world experience | |
dc.subject | treatment response | |
dc.subject | walking ability | |
dc.title | Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience – report of an expert meeting | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Review | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455655900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.volume | 11 | |
plymouth.publication-status | Published | |
plymouth.journal | Therapeutic Advances in Neurological Disorders | |
dc.identifier.doi | 10.1177/1756286418803248 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2018-07-25 | |
dc.rights.embargodate | 2019-12-7 | |
dc.identifier.eissn | 1756-2864 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1177/1756286418803248 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-10-05 | |
rioxxterms.type | Journal Article/Review |